Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus carboplatin-etoposide versus placebo plus carboplatin-etoposide in untreated extensive-stage small cell lung cancer
2019-003063-21Phase 3Completed
- Sponsor
- Henlius
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Serplulimab plus carboplatin-etoposide with Placebo plus carboplatin-etoposide (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Mar 2020; status: completed.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2019-003063-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003063-21.